Patents by Inventor B. Michael Longenecker

B. Michael Longenecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhancement of the cellular immune response
    Patent number: 6326009
    Abstract: DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: December 4, 2001
    Assignee: Biomira, Inc.
    Inventors: B. Michael Longenecker, Carina Henningsson
  • Methods of detecting T-cell activation and treating disorders associated with T-cell dysfunction
    Patent number: 6114129
    Abstract: Methods of detecting activated T-cells involve monitoring levels of MUC-1 mucin expression at the protein and/or mRNA level. Compositions for modulating immune function contain compounds that modulate the expression or function of MUC-1. Methods of treating disorders associated an inappropriate state of T-cell activation involve contacting a T-cell with a compound containing an inhibitor of MUC-1 expression or function.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: September 5, 2000
    Assignee: Biomira, Inc.
    Inventors: Babita Agrawal, B. Michael Longenecker
  • Enhancement of the cellular immune response
    Patent number: 5798090
    Abstract: DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: August 25, 1998
    Assignee: Biomira, Inc.
    Inventors: B. Michael Longenecker, Carina Henningsson
  • Lectin-antibody immunoassays for TF epitope-bearing antigens
    Patent number: 5242799
    Abstract: A heterologous sandwich immunoassay has been developed for human TF antigen using a monoclonal antibody as the catcher and labelled peanut agglutinin as the probe. Since human TF antigen is shed by tumor cells, a positive determination of the TF antigen in a patient sample indicates the presence of cancer. The test can also be used to monitor the course of conventional chemotherapy or radiotherapy by monitoring the amount of TF antigen in a fluid sample from a patient being so treated. Because of the sensitivity of the assay method, cancer can be detected in very early stages by the assay method of the present invention.
    Type: Grant
    Filed: March 4, 1992
    Date of Patent: September 7, 1993
    Assignee: Biomira, Inc.
    Inventors: John Samuel, B. Michael Longenecker
  • Human tumor-associated Thomsen-Friedenreich antigen
    Patent number: 5110911
    Abstract: Human tumor associated Thomsen-Friedenreich (TF) antigen is purified from adenocarcinoma conditioned media, adenocarcinoma cell detergent extracts or plural effusion fluid by affinity chromatography using an insolubilized TF-specific monoclonal antibody, MAb 49H.8. The TF antigen is a glycoprotein characterized by a non-cryptic Gal .beta.(1.fwdarw.3) GalNAc epitope, a molecular weight in excess of 1,000,000 daltons, and extractability with perchloric acid, the epitope being sensitive to alkali and periodate but resistant to acid. A heterologous sandwich immunoassay has been developed for human TF antigen using a monoclonal antibody as the catcher and labelled peanut agglutinin as the probe. Since human TF antigen is shed by tumor cells, a positive determination of the TF antigen in a patient sample indicates the presence of cancer.
    Type: Grant
    Filed: November 2, 1989
    Date of Patent: May 5, 1992
    Assignee: Biomira, Inc.
    Inventors: John Samuel, B. Michael Longenecker
  • Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
    Patent number: 4971795
    Abstract: DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
    Type: Grant
    Filed: July 21, 1988
    Date of Patent: November 20, 1990
    Assignee: Biomira, Inc.
    Inventors: B. Michael Longenecker, Carina Henningsson